Rigid endoscopic lithotripsy devices market seen reaching $6.11B by 2030

The rigid endoscopic lithotripsy devices market is projected to grow from $4.3 billion in 2025 to $6.11 billion by 2030, driven by rising kidney stone cases, more minimally invasive procedures and broader use of laser-based treatments. North America led the market in 2025, according to a new report from The Business Research Company.

Why it matters: - Rigid endoscopic lithotripsy devices support minimally invasive treatment for kidney stones and other urinary tract conditions. - The market's growth signals rising demand for tools that can shorten recovery times and expand outpatient stone treatment. - The report links market expansion to higher healthcare spending, aging populations and more lifestyle-related stone disease.

What happened: - The Business Research Company published its Rigid Endoscopic Lithotripsy Devices Market Report 2026, covering market size, trends and a global forecast through 2035. - The market is projected to rise from $4.3 billion in 2025 to $4.62 billion in 2026. - The report forecasts the market will reach $6.11 billion by 2030. - North America led the global market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Download a free sample of the report. - View the full report.

The details: - The market's 2025-2026 growth implies a 7.5% compound annual growth rate. - The forecast to 2030 reflects a 7.2% compound annual growth rate. - Historical growth has been driven by higher kidney stone prevalence, wider adoption of endoscopic procedures, shorter recovery times, more urology treatments and expanding hospital infrastructure. - Innovation in laser technology is a key driver of future demand. - More outpatient procedures are also supporting growth. - The report highlights a shift toward minimally invasive stone treatments and broader use of laser lithotripsy. - Demand is rising in ambulatory surgical centers and day-care urology procedures. - Device makers are also pushing for smaller and more efficient tools. - Rigid endoscopic lithotripsy devices use a rigid endoscope to reach stones and fragment them with lasers, ultrasonic waves or pneumatic forces. - The devices help remove fragments or allow them to pass naturally. - Bladder cancer is adding to demand because the devices can treat bladder stones and related complications such as obstructions and irritation. - The devices also help remove residual tumors and support efforts to prevent recurrence. - The American Cancer Society's Cancer Facts & Figures 2024 projected U.S. bladder cancer diagnoses rising from 81,180 in 2022 to 83,190 in 2024. - The UK Office for National Statistics reported a 5.6% nominal increase in total healthcare expenditure for 2023 in May 2024, equal to 0.9% growth versus 2022.

Between the lines: - The forecast points to a market that is moving beyond hospital-only use and into faster-turnover care settings. - The combination of laser innovation and smaller device design suggests competition is shifting toward efficiency and procedural convenience. - Bladder cancer is not the main market driver, but it broadens the clinical demand beyond kidney stone treatment alone. - Rising healthcare budgets appear to be helping providers buy more advanced surgical equipment.

What's next: - The market is expected to keep expanding through 2030 as minimally invasive urology procedures gain share. - Wider adoption in ambulatory and day-care settings could further lift procedure volumes. - The report says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards and market hotspot infographics. - The Business Research Company lists Saumya Sahay as a contact for expert inquiries, with phone numbers for the Americas, Asia and Europe and email at marketing@tbrc.info.

The bottom line: - Rigid endoscopic lithotripsy devices are moving with a broader shift toward faster, less invasive urology care, and the market outlook remains firmly positive through 2030.